Isis Pharmaceuticals, Inc. to Receive $7.5 Million From Alnylam
Isis Pharmaceuticals, Inc. recently announced it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. from the recently announced alliance between Genzyme and Alnylam. In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments. This transaction underscores the value of Isis’ innovation and the leadership role Isis has played in the field of nucleic acid based therapeutics.
“Our innovation in RNA-based drug discovery has enabled us to create a broad and extensive patent position that covers many key discoveries for the RNA therapeutic space. The breadth and depth of our patent estate has allowed us to create a number of relationships, such as the one we have with Alnylam, that enhance our leadership in the field. Our technology supports RNA-based drug discovery efforts for us and our partners and allows our partners access to our technology. To date, we have generated well over $400 million from the sales and licensing of our intellectual property, including more than $50 million from Alnylam’s collaborations,” said B. Lynne Parshall, Chief Operating Officer at Isis.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. For more information, visit www.isispharm.com.
Total Page Views: 927
